Hematologic Oncology

How CTCs and Circulating Naked Tumor DNA-as Liquid Biopsies-Will Transform Diagnostic and Management of Oncology Patients

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma

Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia

Mutations known to be involved in hematologic malignancies were found in the blood cells of 2%-3% of individuals over age 40 and 5%-6% of those over age 70.

The investigational chimeric antigen receptor (CAR) therapy CTL019 demonstrated promising activity in 2 pilot trials, eliciting complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL).

Stephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.

The FDA has assigned a priority review designation to blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The combination of ABT-199 and ibrutinib (Imbruvica) demonstrated promising early activity in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) cell lines

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

A preclinical study has shown promising steps toward tackling drug resistance in hematologic malignancies using sequential dosing of drugs targeted against vulnerabilities that emerge as a result of tumor evolution

Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Despite a recent decline in utilization, consolidated radiation therapy has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.